Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride

International Journal of Dermatology

Volumn 53, Issue 11, 2014, Pages 1351-1357

  Jung, Jae Yoon ^a   Yeon, Je Ho ^a   Choi, Jee Woong ^a   Kwon, Soon Hyo ^a   Kim, Beom Joon ^b   Youn, Sang Woong ^a   Park, Kyoung Chan ^a   Huh, Chang Hun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; MINOXIDIL; AZASTEROID; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CUTANEOUS PARAMETERS; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FOLLOW UP; GYNECOMASTIA; HAIR; HAIR DENSITY; HAIR LOSS; HAIR THICKNESS; HUMAN; IMPOTENCE; KOREAN (PEOPLE); LIBIDO DISORDER; MALE; MALE TYPE ALOPECIA; MEDICAL PHOTOGRAPHY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHOTOTRICHOGRAM; PHYSICAL EXAMINATION; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; ALOPECIA; CHEMICALLY INDUCED; PATHOLOGY; PHOTOGRAPHY; RETREATMENT; TREATMENT FAILURE;

5-ALPHA REDUCTASE INHIBITORS; ADULT; ALOPECIA; AZASTEROIDS; FINASTERIDE; HAIR; HUMANS; MALE; PHOTOGRAPHY; RETREATMENT; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT FAILURE;

EID: 84911977247     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12060     Document Type: Article

References (22)

1. Whiting DA. Male pattern hair loss: current understanding. Int J Dermatol 1998; 37: 561-566.
2. Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1998; 24: 1330-1332.
3. Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359-1365.
4. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39: 578-589.
5. McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs 1999; 57: 111-126.
6. Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143: 804-810.
7. Price VH, Menefee E, Sanchez M, et al. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): 3- and 4-year results. J Am Acad Dermatol 2006; 55: 71-74.
8. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41: 555-563.
9. Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 2003; 13: 150-160.
10. Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 1993; 13: 309-325; discussion 325-309.
11. Kawashima M, Hayashi N, Igarashi A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 2004; 14: 247-254.
12. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40: 930-937.
13. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-2184.
14. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-706.
15. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55: 1014-1023.
16. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63: 252-258.
17. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 713-721.
18. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol 2007; 6: 9-13.
19. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12: 38-49.
20. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709-715.
21. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-494; discussion 495.
22. Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496-1502.